Welcome to GlyGenix Therapeutics, Inc.
Focused on restoring metabolism
GlyGenix Therapeutics, Inc. is focused on treating and curing Glycogen Storage Disease Type 1a which is a heritable gene mutation that results in altered metabolic homeostasis. Our expertise in the application of UltraSound-mediated Plasmid DNA delivery (USP) will be unique and will provide a safe in vivo delivery approach for targeting the normal gene to the appropriate tissue. The product opportunities target unmet clinical needs and are expected to represent a significant therapeutic advance. GlyGenix Therapeutics, Inc.'s mission is focused on the development of nucleic acid molecules that compensate or correct the genetic defects that cause Glycogen Storage Disease Type 1a.
GSD1a Facts
- GSD1a is a genetic disorder with a prevalence of 1:100,000 live births.
- Found in almost every culture around the world, it is estimated that 1:68 Ashkenazi Jews are carriers for GSD1a.
- The liver enzyme responsible for blood glucose maintenance is either missing or dysfunctional, making it difficult to maintain normal glucose levels between meals.
- There is no existing medication or cure for this disease.
- Many children need to undergo intensive therapy to relearn sucking, swallowing and speech.